FDA, CDER Discuss AI/ML In Drug Development In Discussion Papers

FDA hopes to engage in “mutual learning” with stakeholders to develop new regulations for the use of AI/ML drug development.

• Source: Shutterstock

The US Food and Drug Administration wants stakeholder input on new regulations for the usage of artificial intelligence and machine learning in drug development.

The first of the FDA’s new discussion papers on AI/ML, titled “

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation